| Literature DB >> 33806106 |
Danilo Marasso1, Corrado Lupo2, Simone Collura1, Alberto Rainoldi2, Paolo Riccardo Brustio2.
Abstract
This study aimed to highlight the relationship between moderate-to-vigorous physical activity (MVPA) as assessed by accelerometer devices and the Physical Activity Questionnaire for Children (PAQ-C) to estimate the convergent validity of the questionnaire. A systematic review and a meta-analysis were applied by collecting pertinent studies (PubMed, Web of Science, PsycINFO, and SCOPUS) from 1997 until November 2020. The relationship between PAQ-C and MVPA scores was estimated considering correlation coefficients such as the effect size. Fisher's transformation was used to convert each correlation coefficient into an approximately normal distribution. The pooled correlations between PAQ-C and MVPA scores were measured by r values after converting the Fisher's z values back into correlation coefficients for presentation. A total of 13 studies were included in the meta-analysis, and a random effects model was adopted. The pooled correlation between PAQ-C and MVPA scores was significant but with a moderate effect size (r = 0.34 [0.29, 0.39], Z = 15.00, p < 0.001). No heterogeneity among the studies was observed (I2 < 25%). In conclusion, the results highlighted a moderate relationship (around 0.30-0.40) between PAQ-C and accelerometer measurements. These results suggested to concurrently administer both tools to reach a more comprehensive description of children's PA, in terms of quality and quantity.Entities:
Keywords: MVPA; PA; accelerometer; children; questionnaire
Year: 2021 PMID: 33806106 PMCID: PMC8036389 DOI: 10.3390/ijerph18073413
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow diagram for screening and selection of studies.
Summary of the studies included in the meta-analysis (alphabetical order).
| Study Information | Study Population | Accelerometer Information | Outcomes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Authors | Location | Years | Sample Size | Mean Age (Range) | Gender (% Girls) | Model (Axis) | Placement | N Days (Weekend) | Epoch Length (s) | Outcomes | Cut-Point PA Intensity Level (Non-Wearing Definition) | h/Day | PAQ-C (Points) | MVPA (min/Day) |
|
| Ben Jemaa et al. [ | Tunisia | 2018 | 40 | 9.34 ± 0.94 | 47.5% | ActiGraph GT3X + | hip | 4 (1) | 15 | ST, LPA, MPA | Evenson et al. | ≥6 | 2.55 ± 0.67 | 59.77 ± 22.01 | 0.119 |
| Benitez-Porres et al. [ | Spain | 2016 | 146 | 10.8 ± 1.3 | 43.1% | ActiGraph GT3X | hip | 7 (1) | 1 | MVPA | Evenson et al. | ≥10 (week) | 3.09 ± 0.64 | 62.80 ± 13.90 | 0.170 ¥ |
| Benitez-Porres et al. [ | Spain | 2016 | 78 | 10.98 ± 1.17 | 46.1% | ActiGraph GT3X | hip | 7 (1) | 1 | MVPA | Evenson et al. | ≥10 (week) | 3.24 ± 0.64 | 63.22 ± 14.40 | 0.248 ¥ |
| Chan et al. [ | China | 2018 | 191 | 9.9 ± 1.0 | 59,7% | ActiGraph GT3X + | hip | 7 (1) | 15 | MVPA | Evenson et al. | ≥6 | 2.67 ± 0.70 | 40.86 ± 14.07 | 0.190 |
| Fairclough et al. [ | England | 2011 | 175 | 10.6 ± 0.3 | 55.4% | ActiGraph GT1M | hip | 5 (1) | 5 | MPA, VPA, MVPA, | Ekelund et al. | ≥6 (week) | 3.39 ± 0.13 (M) | 66.30 ± 3.70 (M) | 0.338 φ |
| Gobbi et al. [ | Italy | 2016 | 55 | 9.5 ± 0.4 | 50.9% | ActiGraph GT3X + | hip | 7 (n.r.) | 15 | MVPA | Evenson et al. | ≥9 | 2.79 ± 0.52 | n.r. | 0.300 ¥ |
| Kowalski et al. [ | Canada | 1997 | 70 | 11.30 ± 1.39 | n.r. | Caltrac | hip | 7 (1) | n.r. | MVPAMVPA > 10min | n.r.(n.r.) | n.r. | 3.32 ± 0.68 | n.r. | 0.390 |
| Labbrozzi et al. [ | Italy | 2012 | 118 | n.r. | 100% | COSMED Lifecorder | hip | n.r. | 4 | LPA, MPA, VPA | Kumahara et al. | n.r. | n.r. | n.r. | 0.456 φ |
| Ni Mhurchu et al. [ | New Zealand | 2008 | 20 | 12 ± 1.5 | 40% | ActiGraph 7164 | hip | 4 (2) | n.r. | PA counts, LPA, MPA, | Freedson et al. | ≥8 | 1.8 ± 0.6 | n.r. | 0.440 φ |
| Saint-Maurice et al. [ | USA | 2014 | 103 | 10.8 ± 2.0 | 52.4% | ActiGraph GT1M | hip | 7 (1) | 30 | MVPA | Freedson et al. | ≥9 | 3.1 ± 0.7 | n.r. | 0.350 |
| Venetsanou et al. [ | Greece | 2020 | 218 | 10.99 ± 1.52 | 56.9% | ActiGraph GT3X + | hip | 7 (1) | 5 | MVPA, steps/day | Evenson et al. | n.r. | 2.70 ± 0.55 (M) φ | 42.46 ± 12.46 (M) φ | 0.354 ¥ |
| 2.78 ± 0.37 (M) | 40.33 ± 11.95 (M) | ||||||||||||||
| Wang et al. [ | China | 2016 | 365 | 10.2 ± 1.1 | 45.2% | ActiGraph GT3X | hip | 7 (1) | 5 | MVPA | Evenson et al. | ≥8 | 2.70 ± 0.70 | 43.10 ± 12.74 | 0.390 |
| Wang et al. [ | China | 2016 | 358 | 10.5 ± 1.1 | 45.8% | ActiGraph GT3X | hip | 7 (1) | 5 | MPA, VPA, MVPA | Evenson et al. | ≥8 | 2.60 ± 0.68 | 43.00 ± 13.72 | 0.330 ¥ |
Notes: n.r., data not reported in the paper; M, male; F, female; SB, Sedentary Behavior; LPA Light Physical Activity; MPA, Moderate Physical Activity; VPA, Vigorous Physical Activity; MVPA, Moderate to Vigorous Physical Activity; WE, weekend; ¥, data are reported as Spearman’s rho; φ, data directly provided by the authors. Cut-point PA intensity level: Evenson’s PA cutoff: SB (0–100 counts/min), LPA (101–2295 counts/min), MPA (2296–4011 counts/min), VPA (≥4012 counts/min); Ekelund’s PA cutoff: SB (<500 counts/min), LPA (501–2000 counts/min), MPA (2001–3999 counts/min), VPA (≥4000 counts/min); Freedson’s PA cutoff: LPA (1.5–2.9 MET), MPA (3.0–5.9 MET), VPA (≥ MET); Kumahara’s PA cutoff: LPA (<3 MET), MPA (3–6 MET), VPA (≥6 MET). PAQ-C, Physical Activity Questionnaire for Children.
The Strengthening the Reporting of Observational Studies in Epidemiology checklist (STROBE) scores and summary of studies’ quality.
| 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# | 9# | 10# | 11# | 12# | 13# | 14# | 15# | 16# | 17# | 18# | 19# | Score/19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ben Jemaa et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 14 |
| Benitez-Porres et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 15 |
| Benitez-Porres et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 17 |
| Chan et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 16 |
| Fairclough et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 16 |
| Gobbi et al. [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 15 |
| Kowalski et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 12 |
| Labbrozzi et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 16 |
| Ni Mhurchu et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 14 |
| Saint-Maurice et al. [ | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 14 |
| Venetsanou et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 16 |
| Wang et al. [ | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 16 |
| Wang et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 16 |
Notes: 0 = Item criterion is absent or insufficient information is provided; 1 = item criterion is present and explicitly described. #1. In the abstract, an informative and balanced summary of what was done and what was found is provided. #2. Explains the scientific background and rationale for the investigation being reported. #3. States clear, specific objectives and/or any prespecified hypotheses. #4. Describes the setting (e.g., school context), locations (e.g., nation), and relevant dates for data collection. #5. Give characteristics of study participants (must include age and gender) and eligibility criteria. #6. Clearly defines all outcomes, potential confounders, and effect modifiers. #7. For each variable of interest, gives sources of data and details of methods of assessment (e.g., information about accelerometer time of wearing, epoch length, wearing position). #8. Describes any efforts to address potential sources of bias (e.g., minimum of daily wearing, statistical treatment of outliers). #9. Checks whether the study used power calculations to ensure the study size was adequately powered to detect hypothesized relationships? #10. Explains how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why. #11. Describes all statistical methods, including those used to control for confounding and any methods used to examine subgroups and interactions (if applicable). #12. Indicates the number of participants with missing data for each variable of interest. #13. Cohort study—Report numbers of outcome events or summary measures over time. #13. Cross-sectional study—Reports numbers of outcome events or summary measures. #14. A measure of effect size is provided (e.g., Cohen’s effect size, Pearson’s r, Spearman’s rho). #15 Provides statistical estimate(s) and precision (e.g., 95% CI) for each sample or subgroup group examined. #16. A summary of key results with reference to study objectives is provided. #17. Discusses limitations of the study, considering sources of potential bias, confounding factors, or imprecision. #18. A cautious overall interpretation of results considering objectives and relevant evidence. #19. Discusses the generalizability of the study results to similar or other contexts. TOTAL/19.
Figure 2Forest plot showing the relative and pooled correlations between PAQ-C and MVPA scores of the included studies.